Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

by patients than Schedule A, while maintaining anti-leukemic activity. Ten of 35 patients on Schedule B have achieved CR or CRp. In addition to improved tolerability, the 30-day all-cause mortality has been reduced to 9%. To date, 16 of the planned 30 patients have been enrolled in Schedule C.
  • Presented interim clinical data of the Phase 1b/2 trial of voreloxin combined with cytarabine in relapsed/refractory AML at the 50th Annual Meeting of the American Society of Hematology, with a year end update that coincided with the 27th Annual J.P. Morgan Healthcare Conference in San Francisco. A maximum tolerated dose of 80 mg/m2 of voreloxin was established for Schedule A (continuous infusion of cytarabine), with 9 CRs or CRps reported in the Phase 1b dose escalation. Early data show that six of fourteen evaluable AML patients in first relapse enrolled in the Phase 2 portion of Schedule A of this trial have achieved CR, with a preliminary 30-day all-cause mortality of less than 10%. In addition, one patient who achieved a partial response proceeded to bone marrow transplant. Enrollment for Schedule A is complete. In Schedule B (a 2 hour intravenous infusion of cytarabine), the third dose escalation cohort, with a dose of 90 mg/m2 of voreloxin, is fully enrolled. Complete remissions have been observed in Schedule B in both relapsed and treatment refractory patients. Enrollment into the Phase 2 portion of Schedule B is expected to begin shortly.
  • Presented updated interim data from an ongoing Phase 2 clinical trial of single-agent voreloxin in platinum-resistant ovarian cancer patients at the 12th Biennial Meeting International Gynecologic Cancer Society, with a year end update that coincided with the 27th Annual J.P. Morgan Healthcare Conference in San Francisco. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. Enrollment of this trial comp
    '/>"/>

  • SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Research and Markets has announced the addition ... report to their offering. The ... and in-depth study on the current state of the ... a basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including development ...
    (Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
    (Date:9/18/2014)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... in the Biotech Industry conference on Friday, September 26, ... Hotel & Conference Center in New York ... at www.meipharma.com . A replay will be available approximately ...
    (Date:9/18/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... separate underwritten offerings of 10,000,000 shares of its Common ... per share, for expected gross proceeds of $20 million ... Stock at a price to the public of $2,000.00 ... Each share of Series A Convertible Preferred Stock is ...
    Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
    ... Tentative FDA Approval and Expects Final Approval Shortly -- , ... (NYSE: HSP ), the world leader in generic ... the District of New Jersey has granted summary judgment of ... medication Eloxatin(R), and that Hospira has tentative approval from the ...
    ... Provide Rich Social Media Experience For WalkMS Participants - ... commitment to those who support friends, family, and other people ... Acorda Therapeutics to relaunch the online component of the "I ... experience through the use of enhanced social media applications. , ...
    ... 18 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ... sale of an additional BARA-MED(R)XD monoplace hyperbaric oxygen chamber ... The state-of-the-art monoplace chamber is among the first computer-controlled ... , , Hyperbaric chambers are used in ...
    Cached Biology Technology:Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3I Walk Because Program Gives Consumers a Voice 2I Walk Because Program Gives Consumers a Voice 3Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 3Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 4
    (Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
    (Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
    (Date:9/18/2014)... Dartmouth researchers and their colleagues have built the ... health, academic performance and behavioral trends. In other ... -- even if you don,t -- and how ... compares students, happiness, stress, depression and loneliness to ... the general population for example, to monitor ...
    Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
    ... graduated in 1978 with a degree in chemical engineering, ... Election to the National Academy of Engineering is ... Academy membership honors those who have made outstanding ... is the commander, Space and Missile Systems Center, Air ...
    ... is available in German . ... is a good thing that can make life a lot easier. For example, ... paying. If everyone had a meal and a drink and you split the ... what they would have paid for their individual meal and drink. However, if ...
    ... high elevations found in residents of the Tibetan plateau ... to contemporary Sherpa. These genes were passed on to ... and then amplified by natural selection in the modern ... scientists from the University of Chicago and Case Western ...
    Cached Biology News:Sometimes the average just isn't good enough 2Sometimes the average just isn't good enough 3The genetic origins of high-altitude adaptations in Tibetans 2The genetic origins of high-altitude adaptations in Tibetans 3
    ... combines shaking and rocking for maximal fluid movement. ... mm stainless steel or acrylic platform, it is ... operation. The platform angle is easily adjusted from ... action and rotation speed of platform is adjusted ...
    ... both gel dimensions in the same cell. Up to ... a single run using the tube gel adaptors, which ... manner as the slab gel assembly. While the tube ... cast in the casting stand. The 20 cm long ...
    ... kit for 25 chips provides the chips ... analysis (at nanogram levels) with the Experion ... RNA StdSens microfluidic chips, 2 x 1,250 ... RNA StdSens stain, 2 x 20 microliters ...
    ... timer, SB3, Fully adjustable mixing angle, Variable ... to hold a number of different sized ... for aerating cultures, keeping biological samples in ... rotator can be used in incubators up ...
    Biology Products: